REPAIRING THE MYELIN SHEATH

Pursuing an Elusive Treatment

Learn More
WE ARE ENDECE

ENDECE, LLC is a privately held biopharmaceutical company focused on discovering and developing new drug therapies to stop or reverse disease progression by controlling key cellular pathways. These therapies exert their control over these pathways by targeting receptors within cell nuclei that regulate certain genes.

Our scientists invented compounds with potential benefit associated with novel mechanisms of action for treating multiple sclerosis (MS) and other neurological diseases. In addition to MS, we focus on diseases whose treatment options are limited or non-existent, whose causes may not be well understood and whose clinical development paths are still undefined.

ENDECE was founded in 2006 and is headquartered in Mequon, Wisconsin.

Learn More

LATEST NEWS

View All

STRUCTURALLY SIMILAR ESTRADIOL ANALOGS UNIQUELY ALTER THE REGULATION OF INTRACELLULAR SIGNALING PATHWAYS.